Temperature-controlled supply chain solutions firm Cryoport has partnered with VGXI, a subsidiary of GeneOne Life Science, to support the development of cell and gene therapies and mRNA-based treatments.
Under terms of the deal, Cryoport will provide biostorage and bioservices for plasmid DNA products manufactured at VGXI’s facilities in the Woodlands, Texas, and its headquarters and manufacturing location, also in Texas.
Jerrell Shelton, CEO of Cryoport, said the partnership underscores the company’s shared commitment to quality and innovation in the cell and gene market.
“Together, we will provide biopharmaceutical companies a comprehensive and integrated solution to support clinical programmes that are developing lifesaving, next-generation therapeutic modalities.”
